STOCK TITAN
  1. Home
  2. News
  3. AKBA

Akebia Therapeutics Inc. - AKBA STOCK NEWS

Welcome to our dedicated news page for Akebia Therapeutics (Ticker: AKBA), a resource for investors and traders seeking the latest updates and insights on Akebia Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Akebia Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Akebia Therapeutics's position in the market.

News
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Akebia Therapeutics, Inc. (Nasdaq: AKBA) granted two new employees options to purchase 31,000 shares of Akebia's common stock on November 30, 2023. The options have an exercise price of $1.06 per share, vest over four years, and have a 10-year term. This grant is in accordance with Nasdaq Listing Rule 5635(c)(4).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Akebia Therapeutics to Present at Piper Sandler Healthcare Conference
Rhea-AI Summary
Akebia Therapeutics, Inc. (Nasdaq: AKBA) announced that CEO John Butler will participate in a fireside chat at the Piper Sandler 35th Annual Healthcare Conference on November 28th. The webcast will be available on Akebia's website for 90 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2%
Tags
conferences
-
News
Akebia Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights
Rhea-AI Summary
Akebia Therapeutics (AKBA) reported financial results for Q3 2023, with net product revenue of $40.1 million for Auryxia. The company's vadadustat NDA was accepted by the FDA with a PDUFA date set for March 27, 2024. Vadadustat is now approved in 36 countries, including Australia and Taiwan. Akebia also modified its loan agreement with Pharmakon, extending the maturity and deferring principal payments.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.93%
Tags
earnings
News
Akebia Therapeutics Announces Favorable Payment Term Modification of Loan Agreement with Pharmakon Advisors
Rhea-AI Summary
Akebia Therapeutics has amended its loan agreement with Pharmakon Advisors, extending the maturity date to March 2025. Quarterly principal payments have been deferred until October 2024, after which monthly principal payments will begin. The amendment strengthens Akebia's cash position and provides flexibility for a potential vadadustat launch.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.9%
Tags
none
-
News
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Akebia Therapeutics, Inc. granted one newly-hired employee options to purchase 61,000 shares of Akebia's common stock. The options have an exercise price of $0.88 per share, vest over four years, and have a 10-year term. This grant was made in accordance with Nasdaq Listing Rule 5635(c)(4).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.23%
Tags
none
-
News
Akebia Therapeutics to Report Third Quarter 2023 Financial Results and Discuss Recent Business Highlights
Rhea-AI Summary
Akebia Therapeutics® (Nasdaq: AKBA) will release its financial results for Q3 2023 on November 8th. A conference call will be held on the same day at 8:00 a.m. ET to discuss the results and recent business highlights.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.02%
Tags
conferences earnings
News
Akebia Receives FDA Acceptance of Resubmission to NDA of Vadadustat for the Treatment of Anemia due to Chronic Kidney Disease
Rhea-AI Summary
Akebia Therapeutics announces FDA acknowledgment of complete resubmission for vadadustat as a treatment for anemia due to chronic kidney disease. FDA sets user fee goal date for March 27, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.65%
Tags
clinical trial
-
News
Akebia Therapeutics Announces Five Poster Presentations at ASN Kidney Week 2023
Rhea-AI Summary
Akebia Therapeutics to present data at ASN Kidney Week 2023, including alternate dosing for vadadustat in the treatment of anemia due to chronic kidney disease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.41%
Tags
none
-
News
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Akebia Therapeutics granted options to purchase 2,000 shares of common stock to a newly-hired employee. The options have an exercise price of $1.14 per share and vest over four years. Each option has a 10-year term.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.71%
Tags
none
News
Akebia Therapeutics Resubmits New Drug Application to the FDA for Vadadustat
Rhea-AI Summary
Akebia Therapeutics has resubmitted its New Drug Application to the FDA for vadadustat, an oral treatment for anemia due to chronic kidney disease. The resubmission includes post-marketing safety data from Japan. A letter from the FDA acknowledging the resubmission is expected in 30 days, with a PDUFA date set for six months from submission.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.86%
Tags
none
Stock AKBA logo
Akebia Therapeutics Inc.

Nasdaq:AKBA

AKBA Rankings

#3449 Ranked by Market Cap
#30 Ranked by Stock Gains
N/A Ranked by Dividends

AKBA Stock Data

293.12M
188.22M
2.47%
26.27%
6.4%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Cambridge

About AKBA

akebia therapeutics, inc. is a biopharmaceutical company headquartered in cambridge, massachusetts, focused on delivering innovative therapies to patients with kidney disease through hypoxia-inducible factor (hif) biology. akebia’s lead product candidate, vadadustat, is an investigational oral therapy in development for the treatment of anemia related to chronic kidney disease in both non-dialysis and dialysis patients. akebia’s global phase 3 program for vadadustat, which includes the pro2tect studies for non-dialysis patients with anemia associated with chronic kidney disease and the inno2vate studies for dialysis-dependent patients, is currently ongoing. for more information, please visit our website at www.akebia.com.